Exposure to GLP-1 receptor agonists has been linked to a lower incidence of certain types of breast cancer. The association between GLP-1 receptor agonist use and breast cancer risk is still being explored, with some reports suggesting a potential reduction in metastatic progression and improved survival. However, the use of these medications has also been associated with other health effects, including an increased risk of osteoporosis and reports of exposures to poison centers.